Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
7177- CHA,    Chaetocin inhibits the progression of neuroblastoma by targeting JAK2/STAT3 signaling pathway in SH-SY5Y cells
- NA, neuroblastoma, SH-SY5Y
AntiCan↑, Inflam↓, tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, JAK2↓, STAT3↓,
7178- CHA,    SUV39H1 Regulates Gastric Cancer Progression via the H3K9me3/ALDOB Axis
- in-vitro, GC, NA
tumCV↓, TumCG↓, SUV39H↓,
7179- CHA,    Chaetocin disrupts the SUV39H1–HP1 interaction independent of SUV39H1 methyltransferase activity
- in-vitro, NA, NA
H3K9↓, SUV39H↓,
7180- CHA,    Chaetocin: A review of its anticancer potentials and mechanisms
- Review, Var, NA
TumCG↓, TumCP↓, Apoptosis↑, TumCCA↑, angioG↓, TumCI↓, TumCMig↓, SUV39H↓, TrxR↓, Hif1a↓, HSP90↓, ox-Trx1↑, ROS↑, PI3K↓, Akt↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, DR5↑, CHOP/DDIT3↑, ATF3↑, angioG↓, VEGF↑, LDHA↓, ENO1↓,
7181- CHA,    Chaetocin induces cell cycle arrest and apoptosis by regulating the ROS-mediated ASK-1/JNK signaling pathways
TumCCA↑, ROS↑, ASK1↑, JNK↑, HMTs↓, Trx↓, tumCV↓, TumCI↓,
7182- CHA,    Chaetocin inhibits IBMX-induced melanogenesis in B16F10 mouse melanoma cells through activation of ERK
- in-vitro, Melanoma, B16-BL6
Mel↓, tyrosinase↓, MITF↓, ERK↑,
7183- CHA,    The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells
- in-vitro, AML, HL-60 - in-vitro, AML, KG-1 - in-vitro, lymphoma, U937
TumCD↓, SUV39H↓, CD11b↑, Diff↑, H3K9↓, eff↑,
7184- CHA,    Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance
- in-vitro, CML, NA
ROS↑, TrxR↓, eff↓, eff↑,
7185- CHA,    Chaetocin-induced ROS-mediated apoptosis involves ATM–YAP1 axis and JNK-dependent inhibition of glucose metabolism
- vitro+vivo, GBM, A172 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HMTs↓, ROS↑, p‑ATM↑, YAP/TEAD↑, p‑JNK↑, TumPF↓, SUV39H↓, TrxR↓, Casp3↑, Trx1↓, H3↓, lactateProd↓, ATP↓, GlucoseCon↓, TumCG↓, Dose↝,
7186- CHA,  TSA,    Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
- in-vitro, AML, NA
SUV39H↓, H3K9↓, eff↑,
7173- CHA,    Natural compound chaetocin induced DNA damage and apoptosis through reactive oxygen species-dependent pathways in A549 lung cancer cells and in vitro evaluations
- in-vitro, Lung, A549
TumCG↓, TumCCA↑, ROS↑, DNAdam↑, CD47↓, *toxicity↓, MMP↓, Casp3↑, mtDam↓,
7171- CHA,    Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201
- vitro+vivo, GBM, DIPG
TumCG↓, TumCP↓, Apoptosis↓, OS↑, H3K9↓, SUV39H↓, eff↑, CSCs↓, SOX9↓, HGF/c-Met↓, FGF21↓, EGFR↓, PDGFR-BB↓, Wnt↓, MYCN↑, OLIG2↓, AURKB↓, HO-1↑, P21↑,
7170- CHA,    Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A–GATA3–STAT3 Circuit
- in-vivo, Bladder, NA
TumCP↓, TumCCA↑, selectivity↑, CSCs↓, SUV39H↓, GATA3↓, STAT3↓, TumCG↓, OS↑,
7168- CHA,    The anticancer effect of chaetocin is enhanced by inhibition of autophagy
- vitro+vivo, Liver, HepG2 - in-vitro, Liver, HepG3 - in-vitro, Liver, HUH7
Apoptosis↓, TumAuto↑, ROS↑, Hif1a↓, SUV39H↓, cl‑PARP↑, eff↑, eff↑,
7167- CHA,    Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism
- vitro+vivo, GBM, A172 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HMTs↓, ROS↑, YAP/TEAD↑, ATM↑, JNK↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, ATP↓, TumCP↓, TrxR↓, Trx1↓, H3K9↓, p‑ATM↑, γH2AX↑, ALDOB↑, ENO3↑, FBP1↑, GSK‐3β↑, HK3↑, PCK1↑, PGK2↑, PGM1↑, PGM3↑, PHKG1↑, PKLR↑, HK2↓, PCNA↓,
7166- CHA,    Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
- vitro+vivo, AML, U937
SUV39H↓, Apoptosis↑, ROS↑, TumCCA↑, tumCV↓, Casp3↑, Casp9↑, Fas↑, FasL↑, DR4↑, P21↑, eff↓, eff↑,
7165- CHA,    The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase
- in-vitro, Cerv, HeLa
ROS↑, TumCD↑, TrxR1↓, other↝, GSR↓, Trx↓, eff↓,
7164- CHA,    Chaetocin induces apoptosis in human melanoma cells through the generation of reactive oxygen species and the intrinsic mitochondrial pathway, and exerts its anti-tumor activity in vivo
- vitro+vivo, Melanoma, A375
TumCP↓, Apoptosis↑, ROS↑, eff↓, MMP↓, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑Casp9↑, Bcl-2↓, TumCG↓, PCNA↓, tumCV↓, NRF2↑, SOD2↑, Catalase↑, NRF2↓, SOD2↓, Catalase↓, TrxR↓,
7163- CHA,    The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
- in-vitro, Lung, A549 - in-vitro, OS, U2OS - in-vitro, CRC, HCT116 - in-vitro, CRC, HeLa - in-vivo, Ovarian, SKOV3
ROS↑, Trx↓, Apoptosis↑, TumCG↓, SUV39H↓, Hif1a↓, TumCP↓, eff↓, MMP↓, TumCG↓, Dose↝, toxicity↓,
7162- CHA,    Chaetocin disrupts the SUV39H1-HP1 interaction independent of SUV39H1 methyltransferase activity
- Study, Nor, NA
*H3K9↓, *other↓, *SUV39H↓,
7161- CHA,    Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases
- Review, Var, NA
H3K9↓, HKMT↓, SUV39H↓, Dose↝,
7160- CHA,    Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress
- in-vitro, Lung, A549
selectivity↑, eff↑, ROS↑, Apoptosis↓, HDAC↓, MMP↓, cl‑PARP↑, eff↑, eff↓, i-GSH∅,
7159- CHA,    ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin
- vitro+vivo, GC, HGC27 - in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, HEK293
TumCP↓, TumCCA↑, Casp↑, Apoptosis↑, TrxR1↓, ROS↑, eff↓, eff↑, PI3K↓, Akt↓, TumCG↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓, TumVol↓, TumW↓, Weight∅, toxicity↓, Ki-67↓, other↝,
2175- Chemo,  VitB12,  FA,    Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients
- Study, BC, NA
other↓, other↝, Hcy/homoC↓, eff↝, other↝,
6025- Chit,    Glycated chitosan as a new non-toxic immunological stimulant
- vitro+vivo, Var, HeLa
*Imm↑, *BioAv↑, eff↑, *toxicity↓, *TNF-α↑, *Obesity↓,
5986- Chit,    The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells
- Study, Var, NA
NK cell↑, IFN-γ↑, IL12↑, IL15↑, STAT4↑, NF-kB↑, DCells↑,
6000- Chit,    Chitosan in Modern Pharmacotherapy: From Drug Encapsulation to Targeted Delivery Systems
- Review, Var, NA
DDS↑, toxicity↓, TJ↓, BioAv↑, *Bacteria↓, *Inflam↓, *antiOx↓, Wound Healing↑, other↝, eff↑, eff↑,
6001- Chit,    Recent advances in engineering chitosan-based nanoplatforms in biotherapeutic multi-delivery for multi-targeted disease treatments: Promises and outlooks
- Review, Var, HepG2 - Review, AD, NA
TumVol↓, toxicity↓, Half-Life↑, eff↑, selectivity↑, Dose↝, *BDNF↑, *NRF2↑, *ROS↓, *neuroP↑, *memory↑, *cognitive↑, *Obesity↓,
5980- Chit,    Chitosan-based nanosystems for cancer diagnosis and therapy: Stimuli-responsive, immune response, and clinical studies
- Review, Var, NA
other↑, Imm↑, DDS↑,
5981- Chit,    Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review
- Review, CRC, NA
DDS↑, eff↑, BioAv↑, BioEnh↑, eff↑,
5982- Chit,    Chitosan Nanoparticles-Based Cancer Drug Delivery: Application and Challenges
- Review, Var, NA
DDS↑, antiOx↑, Bacteria↓, AntiTum↑, Half-Life↑, BioAv↑, toxicity↓,
5983- Chit,    Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy
- Review, BC, NA
DDS↑, BioAv↑, EPR↑, TumCP↓, angioG↓, TumMeta↓, other↑,
5984- Chit,    Chitosan in cancer therapy: a dual role as a therapeutic agent and drug delivery system
- Review, Var, NA
DDS↑, BioAv↑, TumCP↓, angioG↓, TumMeta↓, Apoptosis↑, eff↑,
5985- Chit,  immuno,    Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies.
- Review, Var, NA
TumCP↓, TumW↓, OS↑, eff↑,
5987- Chit,    Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: The Novel Adjuvants for Cancer Vaccine
- Review, Var, NA
other↝, other↝, *Weight↝, *toxicity↓, *Bacteria↓, *BioAv↑, DDS↑, *Wound Healing↑, *other↝, *Imm↑, eff↑, *BioAv↝, *BioAv↑, eff↑, NK cell↑, IL2↑, IFN-γ↑, IL10↑,
5988- Chit,    Chitosan immunomodulation: insights into mechanisms of action on immune cells and signaling pathways
- Review, Var, NA
DDS↑, *Cartilage↑, *Wound Healing↑, Imm↑, cGAS–STING↑, STAT1↑, NLRP3↑, *DCells↑, *IL10↓, *TGF-β1↓, *TNF-α↓, IL1β↓, ROS↑,
5989- Chit,    Chitosan: A review of molecular structure, bioactivities and interactions with the human body and micro-organisms
- Review, Var, NA
Wound Healing↑, Imm↑, AntiTum↑,
5991- Chit,    Chitosan-Based Nanoencapsulated Essential Oils: Potential Leads against Breast Cancer Cells in Preclinical Studies
- Review, BC, NA
*other↝, *BioAv↓, eff↑, toxicity↓, eff↑, TumCD↑, Half-Life↑, selectivity↑, EPR↑, ROS↑, Apoptosis↑, eff↑,
5999- Chit,    How chitosan can help against breast cancer
- Review, BC, NA
eff↑, DDS↑, Half-Life↑, eff↑, eff↑,
5998- Chit,    Trial: Chitosan can help reduce AGE levels in patients with prostate cancer.
- Trial, Pca, NA
AGEs↓, Wound Healing↑, Obesity↓,
5997- Chit,    Using immunoadjuvant agent glycated chitosan to enhance anti-cancer stem like cell immunity induced by HIFU
- in-vivo, Lung, NA
Imm↑, TumMeta↓, eff↑,
5996- Chit,    NEW CHITOSAN-BASED CHEMO PHARMACEUTICAL DELIVERY SYSTEMS FOR TUMOR CANCER TREATMENT: SHORT-REVIEW
- Review, Var, NA
BioAv↑, Wound Healing↑, DDS↑, toxicity↓, eff↑,
5995- Chit,  CUR,    Enhancement of anticancer activity and drug delivery of chitosan-curcumin nanoparticle via molecular docking and simulation analysis
- vitro+vivo, Var, NA
eff↑, EPR↑, DNAdam↑, TumCCA↑, ROS↑, toxicity↓,
5994- Chit,    Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action
- Review, Var, NA
angioG↓, *Imm↑, *antiOx↑, selectivity↑, other↝, toxicity↓, BioAv↑, eff↝, Half-Life↑, MPT↑, MMP9↓, lipid-P↑, EPR↑, NK cell↑, Casp3↑, Casp8↑, TumCCA↑, ROS↑, DDS↑, VEGF↓, TIMP1↑, ChemoSen↑, eff↑,
5993- Chit,    In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy
- in-vitro, Var, NA
Imm↑,
5992- Chit,    Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma
- in-vitro, Melanoma, B16-F10
eff↑, DDS↑,
5990- Chit,    Chitosan Nanoparticles for Targeted Cancer Therapy: A Review of Stimuli-Responsive, Passive, and Active Targeting Strategies
- Review, Var, NA
DDS↑, eff↓, *Bacteria↓, *antiOx↑, *Wound Healing↑, *Imm↑, TumCP↓, TumMeta↓, angioG↓, Apoptosis↑, ROS↑, ER Stress↑, BioAv↑, Half-Life↑, eff↑, EPR↑, ChemoSen↑, eff↑,
4478- Chit,    Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, BC, T47D
TumCP↓, selectivity↑, MMP↓, ROS↑, TumCCA↑, Apoptosis↑, Casp3↑,
4477- Chit,    Recent Advances in Chitosan and its Derivatives in Cancer Treatment
- Review, NA, NA
*BioAv↑, AntiTum↑, eff↑, TumCG↓, angioG↓, TumMeta↓, eff↑, *toxicity↓, other↝,
4476- Chit,    Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial
- Trial, NA, NA
*LDL↓,

Showing Research Papers: 2151 to 2200 of 7378
Prev Page 44 of 148 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7378

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ALDOB↑, 1,   AURKB↓, 1,   CD47↓, 1,   ENO3↑, 1,   H3K9↓, 6,   HK3↑, 1,   HKMT↓, 1,   Mel↓, 1,   MITF↓, 1,   MYCN↑, 1,   OLIG2↓, 1,   PGK2↑, 1,   PGM3↑, 1,   PHKG1↑, 1,   PKLR↑, 1,   SUV39H↓, 12,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ATF3↑, 1,   Catalase↓, 1,   Catalase↑, 1,   i-GSH∅, 1,   GSR↓, 1,   HO-1↑, 1,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↑, 19,   SOD2↓, 1,   SOD2↑, 1,   Trx↓, 3,   Trx1↓, 2,   ox-Trx1↑, 1,   TrxR↓, 5,   TrxR1↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   MMP↓, 5,   MPT↑, 1,   mtDam↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ENO1↓, 1,   FBP1↑, 1,   FGF21↓, 1,   GlucoseCon↓, 2,   HK2↓, 1,   lactateProd↓, 2,   LDHA↓, 1,   PCK1↑, 1,   PGM1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↓, 3,   Apoptosis↑, 11,   ASK1↑, 1,   BAX↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 2,   Casp↑, 1,   Casp3↑, 6,   cl‑Casp3↑, 2,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 2,   Cyt‑c↑, 1,   DR4↑, 1,   DR5↑, 1,   Fas↑, 1,   FasL↑, 1,   HGF/c-Met↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   Mcl-1↓, 2,   survivin↓, 1,   TumCD↓, 1,   TumCD↑, 2,   YAP/TEAD↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

SOX9↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,   other↓, 1,   other↑, 2,   other↝, 9,   tumCV↓, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,   HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   p‑ATM↑, 2,   DNAdam↑, 2,   cl‑PARP↑, 4,   PCNA↓, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 2,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 2,   Diff↑, 1,   ERK↑, 1,   GATA3↓, 1,   GSK‐3β↑, 1,   HDAC↓, 1,   HMTs↓, 3,   PI3K↓, 2,   STAT1↑, 1,   STAT3↓, 2,   STAT4↑, 1,   TumCG↓, 11,   tyrosinase↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

CD11b↑, 1,   Ki-67↓, 1,   MMP9↓, 1,   TIMP1↑, 1,   TJ↓, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 12,   TumMeta↓, 5,   TumPF↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   EGFR↓, 1,   EPR↑, 5,   Hif1a↓, 3,   PDGFR-BB↓, 1,   VEGF↓, 1,   VEGF↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

DCells↑, 1,   IFN-γ↑, 2,   IL10↑, 1,   IL12↑, 1,   IL15↑, 1,   IL1β↓, 1,   IL2↑, 1,   Imm↑, 5,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↑, 1,   NK cell↑, 3,  

Cellular Microenvironment(tgid=17) ⓘ

cGAS–STING↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   NLRP3↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 8,   BioEnh↑, 1,   ChemoSen↑, 2,   DDS↑, 13,   Dose↝, 4,   eff↓, 8,   eff↑, 35,   eff↝, 2,   Half-Life↑, 6,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   Hcy/homoC↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 3,   Obesity↓, 1,   OS↑, 3,   toxicity↓, 9,   TumVol↓, 2,   TumW↓, 2,   Weight∅, 1,   Wound Healing↑, 4,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 162

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

H3K9↓, 1,   SUV39H↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 2,   NRF2↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↝, 2,  

Migration(tgid=13) ⓘ

Cartilage↑, 1,   TGF-β1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

DCells↑, 1,   IL10↓, 1,   Imm↑, 4,   Inflam↓, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 4,   BioAv↝, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,   Obesity↓, 2,   toxicity↓, 4,   Weight↝, 1,   Wound Healing↑, 3,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 3,  
Total Targets: 29

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page